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Abstract
Induction of apoptosis plays a crucial role in the response of tumors to treatment. Thus, we investigated the phar-
macodynamics and tumor saturation kinetics of a death receptor 5 antibody (anti-DR5) when combined with
chemotherapeutics. For our investigations, we applied an imaging method that allows monitoring of apoptosis non-
invasively in living mice. A stably transfected apoptosis reporter based on split luciferase technology facilitates
to screen various chemotherapeutics and anti-DR5 on their ability to induce apoptosis in glioblastoma cells in vitro
as well as in vivo. We found that doxorubicin (DOX) treatment in vitro led to significant apoptosis induction within
48 hours and to a 2.3-fold increased anti-DR5 binding to the cell surface. In contrast, cisplatin and 5-fluorouracil
(5-FU) treatment altered anti-DR5 binding only marginally. Induction of apoptosis by treatment with anti-DR5 was
dose- and time-dependent (both in vitro and in vivo). Simultaneous visualization of fluorescence-labeled anti-DR5
in tumor tissue and apoptosis revealed maximal apoptosis induction immediately after the compound had reached
tumor site. Regarding combination therapy of anti-DR5 and DOX, we found that the sequential application of DOX
before anti-DR5 resulted in synergistically enhanced apoptosis reporter activity. In striking contrast, anti-DR5 given
before DOX did not lead to increased apoptosis induction. We suggest that DOX-induced recruitment of DR5 to
the cell surface impacts the enhanced apoptotic effect that can be longitudinally monitored by apoptosis imaging.
This study demonstrates that the combination of apoptosis and fluorescence imaging is an excellent method for
optimizing dosing and treatment schedules in preclinical cancer models.
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Introduction
The ability of cancer cells to evade apoptosis is one of the hallmarks of
cancer [1]. To target cancer cells effectively, it is necessary to treat them
with combinations of anticancer drugs that reinforce the programmed
cell death through the well-characterized intrinsic and extrinsic
apoptosis pathways [2].
The intrinsic apoptosis pathway can be activated by chemothera-
peutic compounds that often lead to DNA damage and cell cycle ar-
rest [3]. This pathway signals through caspase-9 and is highly regulated
by p53 and numerous antiapoptotic [e.g., Bcl-2, survivin, X-linked
inhibitor of apoptosis protein (XIAP)] and proapoptotic proteins.
The extrinsic apoptosis pathway is initiated after binding of,
e.g., TNF-related apoptosis-inducing ligand (TRAIL) to its death
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domain–containing receptors (DR4 and 5). The activated death domain
cleaves procaspase-8 to caspase-8 [4]. Another substrate of caspase-8 is
the BH-3 interacting domain death agonist (Bid). Cleaved Bid triggers
cytochrome c release out of mitochondria linking the extrinsic and in-
trinsic apoptosis pathway [5]. Both pathways end in the activation
of the effector caspases-3/7 that ultimately cleave cellular proteins at
specific aspartate-glutamate-valine-aspartate (DEVD) cleavage sequence
for caspases-3/7 and cause apoptosis [6].
The death receptors (DRs) are attractive targets for anticancer treat-
ments. Treatments of tumor cells and tumors in preclinical models with
human recombinant TRAIL achieved impressive anticancer effects, but
its application for anticancer treatment is limited because of resistance
development to TRAIL and its short half-life in serum [7,8]. Activating
monoclonal antibodies to DRs with longer half-lives have already been
developed, e.g., drozitumab that is a human agonistic antibody to DR5
and directly induces apoptosis by DR5 clustering through the extrinsic
pathway [9,10].
Monitoring apoptosis in vivo would lead to a better understanding
of the pharmacodynamics of such proapoptotic compounds. Further-
more, dosing, scheduling, and combinations of these compounds can
be refined in preclinical settings by aiming to maximize the apoptotic
effect. Especially, the sequential application of anticancer drugs target-
ing different proliferation or apoptosis pathways showed promising
enhanced apoptotic effects in some xenograft models [11,12]. The
time-staggered scheduling could lead to a synergistic effect owing to
a higher susceptibility of tumor cells for second-line treatment after
pretreatment [13]. The potential of such scheduled combinations to
enhance apoptosis could be assessed in more detail by monitoring
apoptosis in animal studies over time.
Thus, we applied a bioluminescence-based method that allows
highly sensitive and noninvasive monitoring of apoptosis in living
mice during treatment [14,15]. We showed recently that biolumines-
cence imaging is a valuable and reliable technique for evaluation of
drug efficacy [16]. For monitoring apoptosis by bioluminescence im-
aging, an apoptosis reporter construct is stably transfected in the tu-
mor cell line of interest. This construct consists of two split luciferase
(Luc) components (C-Luc and N-Luc) that are separated by a specific
DEVD cleavage sequence for effector caspases-3/7 (Figure 1). Con-
stitutive expression of the construct is achieved by an upstream
EF1-α promoter. Upon caspase-3/7 activation in apoptotic cells, the
expressed reporter constructs are cleaved at the DEVD site leading to
the complementation of C-Luc and N-Luc to form a functional Luc
enzyme. This bioluminescence-based method offers a high signal-to-
noise ratio resulting in a highly sensitive approach for monitoring ap-
optosis during treatment in human cancer xenografts [17]. In addition,
it allows a comprehensive monitoring of apoptosis because the detected
effector caspases-3 and -7 are common players in the intrinsic as well
as in the extrinsic apoptosis pathway (Figure 1).
We implemented this apoptosis reporter system in a subcutaneous
xenograft model of the human glioblastoma multiforme (GBM) cell
line D54. This cancer type has high medical needs due to median
survival times of approximately 1 year after diagnosis despite standard-
of-care treatment with temozolomide and radiotherapy [18]. An impor-
tant issue is to investigate alternative treatments and to improve therapy
strategies in preclinical settings. Thus, we used the apoptosis reporter
to monitor apoptotic cell death in subcutaneous GBM tumors through
optimizing dosing, schedule, and combination therapies of com-
pounds targeting the intrinsic apoptosis pathway [e.g., cisplatin and
doxorubicin (DOX)] and the extrinsic pathway (anti-DR5 antibody).
Materials and Methods
Reagents and Anti-DR5 Generation
Anti-DR5 antibody, a fully human agonistic monoclonal anti-
body to DR5, was kindly provided by Roche Glycart AG (Schlieren,
Switzerland). For generation of the monoclonal anti-DR5 antibody,
the variable light and heavy chains were synthesized on the basis of
the antibody sequences included in the patent application US 2007/
0031414 A1 [19]. The variable genes were fused in frame with
Figure 1. Schematic illustration of the caspase-3/7 GloSensor reporter activation in apoptotic cells.
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human IgG1 constant κ and constant heavy chain, respectively, in
standard mammalian expression vectors. The anti-DR5 antibody
was transiently produced in HEK293 EBNA cells and purified by
standard Protein A chromatography followed by size exclusion
chromatography. Anti-DR5 was labeled in-house with Alexa Fluor
750 (A750) by monoreactive N -hydroxysuccinimide ester for spe-
cific labeling of amine residues according to the manufacturer’s in-
structions (Invitrogen, Hamburg, Germany). The chemotherapeutic
DOX (Hexal AG, Holzkirchen, Germany) was used for in vivo and
in vitro studies. In addition, staurosporine (Roche Diagnostics GmbH,
Mannheim, Germany), rhTRAIL (R&D Systems, Minneapolis,
MN), temozolomide (Sigma-Aldrich, St Louis, MO), docetaxel
(Sanofi-Aventis, Paris, France), cisplatin, 5-fluorouracil (5-FU), and
irinotecan (all Medac, Hamburg, Germany) were tested in vitro.
D-Luciferin firefly potassium salt was purchased from Biosynth AG
(Staad, Switzerland).
Cell Lines and Culture
D54–caspase-3/7 GloSensor cell line, developed by the Depart-
ment of Radiation Oncology and Radiology, University of Michigan
(Ann Arbor, MI) [15,17], was cultured in RPMI 1640 medium
(PAN Biotech GmbH, Aidenbach, Germany) supplemented with
2 mM L-glutamine, 10% FBS (both PAN Biotech GmbH), and
200 μg/ml G-418 (Roche Diagnostics GmbH).
Bioluminescence Assays
D54–caspase-3/7 GloSensor expressing cells (15,000 cells per
well) were seeded in white clear bottom 96-well plates (PerkinElmer,
Groningen, Netherlands) and incubated for 24 hours. Cells were
treated with various compounds in different concentrations for 4, 24,
and 48 hours. D-Luciferin (300 μg/ml) was added to each well and
bioluminescence signals were measured 5 minutes after luciferin ad-
dition by Safire2 reader (Tecan Group Ltd, Männedorf, Switzerland).
Sequential application was performed by adding the second drug
18 hours after first drug, and bioluminescence signals were measured
6 hours after first drug, 6 and 26 hours after second drug application.
Subsequently, CellTiter-Glo solution (Promega, Madison, WI) was
added to each well to determine cell viability according to the user’s
instructions. Bioluminescence signals were measured 5 minutes after
CellTiter-Glo substrate addition by Safire2 reader. Interfering influ-
ences of both bioluminescence-based assays were excluded by control
experiments. The signals of the apoptosis reporter assay were divided
by CellTiter-Glo signals to minimize bias caused by lower living cell
counts in treated wells. This ratio was divided by mean ratio of un-
treated wells at the distinct time points to get fold induction.
Homogeneous Caspase Assay
D54–caspase-3/7 GloSensor cells (15,000 cells per well) were
seeded in black clear bottom 96-well plates (PerkinElmer) and incu-
bated for 24 hours. Cells were treated with various compounds in
different concentrations for 4, 24, and 48 hours. The Homogeneous
Caspase Assay (Roche Diagnostics GmbH) was performed accord-
ing to the user’s instructions. Fluorescence signals were measured by
Safire2 reader. Fluorescence signals were divided by CellTiter-Glo
signals and mean ratio of untreated wells at 4, 24, or 48 hours.
Flow Cytometric Analysis
D54–caspase-3/7 GloSensor cells (1 × 106 per six-well plate) were
left untreated or treated with 1 μg/ml anti-DR5, 1 μMDOX, 10 μM
cisplatin, or 100 μM 5-FU, respectively, for 18 hours. Cells were har-
vested and washed in phosphate-buffered saline (PBS). After protein
blocking for 15 minutes, 4 μg/ml anti-DR5–A750 diluted in BD
Pharmingen Stain Buffer (BSA; BD Pharmingen, San Jose, CA) was
incubated for 30 minutes on ice. Sodium azide (NaN3) in the Stain
Buffer prevents anti-DR5–A750 from internalization. After washing
twice in Stain Buffer, the cells were resuspended in Stain Buffer for
fluorescence-activated cell sorting (FACS) analysis. Alternatively,
cells were incubated (20 minutes, 4°C) with BD Cytofix/Cytoperm
(BD Pharmingen) for permeabilization of the cell membrane before
anti-DR5–A750 incubation. Washing steps and antibody dilution
were then done with BD Perm/Wash Buffer (BD Pharmingen).
Human IgG (Life Technologies, Darmstadt, Germany), in-house
labeled with A750, was used as an isotype control. FACS was per-
formed using MACSQuant Analyzer (Miltenyi, Bergisch Gladbach,
Germany), and results were analyzed by FlowJo software (FlowJo,
Ashland, OR).
Immunofluorescence Staining
D54–caspase-3/7 GloSensor cells (200,000 cells) were seeded on
Millicell EZ slides (Millipore, Tullagreen, Ireland) and left untreated
or treated with 1 μMDOX for 18 hours. Cells were then permeabilized
with BD Cytofix/Cytoperm for 20 minutes at 4°C and washed twice
with BD Perm/Wash Buffer before incubating 1 μg/ml anti–Golgin-
97 antibody (Invitrogen, Eugene, OR) for 30 minutes at 4°C. After
washing twice, a mixture of 5 μg/ml Hoechst 33342 (BD Pharmingen),
1 μg/ml Alexa 488–labeled Cholera toxin subunit B, 2 μg/ml Alexa
Fluor 647 goat anti-mouse IgG1 (both Invitrogen), and 4 μg/ml
anti-DR5–A750 was incubated for 30 minutes at 4°C. Slides were
washed twice with PBS and analyzed by multispectral fluorescence
microscopy using Pannoramic 250 1.14 slide scanner and Pannoramic
Viewer 1.15 (3DHISTECH, Budapest, Hungary). For cell sur-
face binding studies, anti-DR5–A750 (4 μg/ml) was incubated in
BD Pharmingen Stain Buffer (BSA) for 30 minutes at 4°C before
cell permeabilization.
Human Apoptosis Array
D54–caspase-3/7 GloSensor cells (1 × 106 cells per six-well plate)
were left untreated or treated with 1 μg/ml anti-DR5, 1 μM DOX,
the combination of both given simultaneously, anti-DR5 18 hours
before DOX, or reverse. Cells were lysed 18 hours after single treat-
ment or 24 hours after combination treatment, and Human Apoptosis
Array Kit (R&D Systems) was performed according to the user’s
instructions. Briefly, 250 μg of protein was incubated overnight on
each nitrocellulose membrane. After washing thrice, Detection Anti-
body Cocktail (diluted 1:100) was incubated for 1 hour, followed by
washing thrice and incubation of streptavidin-HRP (diluted 1:2000)
for 30 minutes. After another washing step, Chemi Reagent Mix was
added and the signals on the membranes were developed. The pixel
volume of the spot signals was quantified by ImageQuant TL (GE
Healthcare, Little Chalfont, United Kingdom) and normalized to
reference spots.
Western Blot Analysis
Cells were treated and lysed as described in the Human Apoptosis
Array section. Protein solution (15 μg) was mixed with NuPAGE
LDS Sample Buffer and NuPAGE Sample Reducing Agent, heated
at 75°C for 10 minutes, and run on a NuPAGE 4% to 12% gradient
sodium dodecyl sulfate gel (all Invitrogen, Carlsbad, CA). After the gel
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was blotted on a nitrocellulose membrane, the membrane was blocked
in 1 × NET Buffer for 2 hours. Subsequently, 1 μg/ml rabbit anti-
human Bid antibody (R&D Systems) was incubated for 2 hours at
room temperature. After washing thrice in NET Buffer, anti-rabbit
IgG HRP antibody (diluted 1:2000; Cell Signaling Technology, Dan-
vers, MA) was incubated for 1 hour at room temperature. After washing
thrice in NET Buffer, blots were developed. Rabbit polyclonal anti-
body to β-actin (diluted 1:4000; Abcam, Cambridge, United Kingdom)
was used as a loading control and was incubated overnight.
Subcutaneous Xenograft Model
Female severe combined immunodeficient/beige (SCID beige)
and SCID hairless outbred mice were obtained from Charles River
(Sulzfeld, Germany) and were 9 to 12 weeks of age at initiation of
experiments. Five million D54–caspase-3/7 GloSensor cells in 100 μl
of PBS were inoculated in the right flank of each mouse under 2%
isoflurane anesthesia. After the tumors had grown to approximately
200 to 250 mm3 in volume, the animals were randomized in therapy
groups (five mice per group) according to their basal bioluminescence
signal and their tumor volume. Treatment compounds were given
intravenously through the tail vein of mice. Length (L) and width
(W ) of the tumors were measured by caliper everyday, and tumor
volumes were calculated as (L × W 2)/2 with L ≥ W . All animal
studies were approved by the local government (File No. 55.2-1-54-
2532.2-26-09).
Bioluminescence Imaging
Mice were injected intraperitoneally with a single dose (100 μl) of
D-luciferin (150 mg/kg in PBS) 10 minutes before measurement.
Bioluminescence imaging was performed with IVIS spectrum (Caliper
Life Sciences, Hopkinton, MA) under constant isoflurane (2%) anes-
thesia. The acquired bioluminescence signals in a region of interest
(ROI) over the tumor site were read out as total flux radiance (p/sec/
cm3/sr) with Living Image software (Caliper Life Sciences). Every ROI
signal was divided by the related tumor volume and by the appropriate
ratio of bioluminescence signal to tumor volume at start point 0 hour
to get fold induction. At the application day of the drug, mice were
measured three times followed by measurements every 1 to 3 days.
Fluorescence Imaging
Fluorescence imaging of mice treated with anti-DR5–A750 was
performed with IVIS spectrum directly subsequent to bioluminescence
imaging to allow co-localization of both readouts. “AF750” as filter
setting was chosen in the Imaging Wizard controller of Living Image.
Fluorescence signal intensities were determined by manual spectral
unmixing of acquired images and ROI analysis over the tumor site.
Spectrum of A750 was acquired by measuring anti-DR5–A750 solu-
tion in a black 96-well plate.
Necropsy and Histologic Analysis
Mice were sacrificed by transcervical dislocation. Subcutaneous
tumors were explanted, fixated in 10% formalin, dehydrated, and
blocked in paraffin. Paraffin sections (2.5 μm) were stained with
human/mouse cleaved caspase-3 monoclonal antibody (R&D Sys-
tems, Wiesbaden, Germany) on a Discovery XT (Ventana Medical
Systems, Tucson, AZ). Briefly, cleaved caspase-3 antibody was incu-
bated for 60 minutes, followed by a washing step and incubation of
UltraMap anti-rabbit HRP (Ventana Medical Systems) for 16 min-
utes. Finally, the sections were counterstained with hematoxylin. To
determine the proliferation status of the tumors, paraffin sections
were stained with CONFIRM anti–Ki-67 (clone 30-9) rabbit mono-
clonal antibody on a BenchMark XT (both Ventana Medical Systems).
Slides were analyzed by bright-field microscopy using Pannoramic
250 1.14 slide scanner and Pannoramic Viewer 1.15 (3DHISTECH).
Anti-DR5–A750 accumulation in tumor tissue was analyzed by multi-
spectral fluorescence microscopy using Pannoramic 250 1.14 slide
scanner and Pannoramic Viewer 1.15.
Statistical Analysis
All data values are represented as mean + SEM. Statistical analysis
was performed using JMP8 software (SAS, Cary, NC). Two-sided
t test was applied for in vitro studies with normally distributed
values. For animal studies, the areas under the curve were calculated
and Wilcoxon test was applied. P values < .05 were considered as
statistically significant.
Results
Screening for Apoptosis-Inducing Compounds
To find appropriate apoptosis-inducing compounds for sub-
sequent in vivo therapy studies, various chemotherapeutics and
therapeutic antibodies were screened for their ability to activate
the bioluminescence apoptosis reporter in vitro. D54–caspase-3/7
GloSensor expressing cells were treated with different concentrations
of the compounds for 4, 24, and 48 hours, and bioluminescence
signals were quantified (Figure 2A). Anti–DR5-treated cells showed
up to 38-fold induction in signal intensities within the first 4 hours
compared to untreated cells. TRAIL strongly activated the apoptosis
reporter (up to 29-fold induction) and showed similar dynamics com-
pared to anti-DR5. Chemotherapeutics DOX (1 μM) and cisplatin
(100 μM) caused maximal effects with six- and nine-fold induc-
tion, respectively, only after 48 hours. The standard-of-care chemo-
therapeutic for GBM therapy, temozolomide, led to a moderate
3.5-fold increase after 24 to 48 hours. Other treatments (e.g., 5-FU and
irinotecan) did not show any significant increase in signal intensities.
To verify the induction of the apoptosis reporter activity, the
fluorescence-based Homogeneous Caspase Assay was performed for
a subset of compounds (Figure 2B). This assay, which measures
caspase-3/7 activity through cleavage of DEVD–Rhodamine 110
to free, fluorogenic Rhodamine 110, confirmed the increased bio-
luminescence signals due to caspase-3/7 activation with good correla-
tions (coefficient of determination R2 = 0.79; Figure 2C).
Dosage Optimization of Anti-DR5
To evaluate the bioluminescence apoptosis reporter in vivo, SCID
beige mice bearing subcutaneous D54–caspase-3/7 GloSensor tumors
were treated with two different doses of anti-DR5 (1 and 3 mg/kg).
Mice receiving higher dose showed maximal tumor bioluminescence
signals with 66-fold increase within 6 hours after treatment, whereas
low-dose treatment led to up to 31-fold induction compared to vehicle
(Figure 3, A and B). After 24 hours, the signals declined below 30-fold
induction. The higher dose (3 mg/kg) kept the signals between 23- and
31-fold induction over 7 days, whereas the apoptosis reporter activity
in tumors of mice treated with the 1 mg/kg dose decreased to 15- to
23-fold induction. After 8 days, both treatment groups showed con-
siderably lower apoptosis reporter activities, indicating an appropriate
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time point for re-dosing. Re-application led instantly to increased
reporter activities. Considering the whole treatment period, apoptosis
induction by high-dose treatment is statistical significant compared to
low-dose treatment (P < .02), and both dosages of anti-DR5 are highly
significant compared to vehicle (P < .01). Immunohistochemical
analysis of explanted tumor tissues at the end point verified increased
active caspase-3 levels in anti–DR5-treated tumors (Figure 3C ).
Simultaneous Apoptosis and Fluorescence Imaging
Next, we wanted to investigate the mechanism of action of anti-DR5
in detail by combining pharmacodynamics with tumor saturation
kinetics. Treatment of mice with 3 mg/kg A750-labeled anti-DR5
allowed additional kinetics studies of antibody accumulation in the
tumor through fluorescence imaging. The highest fluorescence signals
were already detected 6 hours after initiation of treatment, whereas
the maximal apoptosis induction, measured by bioluminescence im-
aging, was evoked slightly time-shifted at 12 hours after antibody
application. In contrast, maximal tumor growth inhibition was reached
only after 5 days (Figure 4A). This emphasized the fast apoptosis
induction through the extrinsic pathway and the lagged efficacy
on tumor growth after initiation of programmed cell death. Over time,
the antibody dissociated from the tumor with 50% dissociation after
3 days, whereas the apoptosis reporter activity was steadily elevated
for more than 8 days after an initial activity peak. Successful re-
application of anti-DR5 was monitored by reconstituted accumulation
of the fluorescence-labeled antibody in the tumor resulting instantly to
increased apoptosis reporter activities and time-lagged, reinforced
tumor growth inhibition. Co-localization of bioluminescence signals
with subsequently acquired fluorescence signals demonstrated the
binding of anti-DR5–A750 to D54–caspase-3/7 GloSensor tumor
cells in vivo (Figure 4B). Compared to unlabeled anti-DR5, A750-labeled
anti-DR5 showed almost identical pharmacodynamics (Figures 3 and 4).
Figure 2. In vitro evaluation of bioluminescence apoptosis reporter in D54 tumor cells. (A) Screening with various anticancer compounds in
different concentrations for 4, 24, and 48 hours of incubation on their ability to activate the apoptosis reporter. Staurosporine (STS) served as
a positive control. Bioluminescence signals were normalized to cell viability and expressed in fold induction compared to untreated samples;
n = 4. (B) Fluorescence-based Homogeneous Caspase Assay was performed for a subset of treatments. Fluorescence signals were
normalized to cell viability and expressed in fold induction compared to untreated samples; n = 3. (C) Correlation analysis of apoptosis
reporter activities to Homogeneous Caspase Assay activities.
Neoplasia Vol. 15, No. 8, 2013 Monitoring Apoptosis in Mice Weber et al. 867
Combination of Anti-DR5 with Chemotherapeutics
Numerous in vitro and in vivo data have been published demon-
strating that the combined application of two anticancer compounds
enhances apoptosis [11,13,20]. Especially, the sequential application
of two drugs that target different proliferation or apoptosis pathways
seems to be promising [21].
Thus, we investigated apoptosis reporter activities after sequential
treatment of D54–caspase-3/7 GloSensor cells with anti-DR5 and
Figure 4. Pharmacodynamics and tumor saturation kinetics after anti-DR5–A750 application. (A) Time courses of mean bioluminescence
apoptosis reporter activities, mean fluorescence signals (anti-DR5–A750 accumulation in the tumor), and mean tumor growth inhibition
(compared to untreated control group). Fluorescence signals were maximal at 6 hours, bioluminescence signals after 12 hours, and
tumor growth inhibition after 5 days. (B) Representative bioluminescence, fluorescence, and overlay images of mice treated with 3 mg/kg
anti-DR5–A750 12 hours after first treatment; n = 5.
Figure 3. Dosage and application optimization of anti-DR5 in vivo. (A) Time course of bioluminescence apoptosis reporter activities in
untreated mice and mice treated with 1 or 3 mg/kg anti-DR5, respectively. Second treatment was applied 8 days (192 hours) after first
treatment; n = 5. (B) Representative bioluminescence images of untreated mice and mice treated with 1 or 3 mg/kg anti-DR5 12 hours
after first treatment. Signals are expressed in radiance (p/sec/cm3/sr). (C) Representative immunohistochemical sections stained on
active caspase-3 (brown) at end point. Cell nuclei were counterstained with hematoxylin (blue). Original magnification, ×400.
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DOX, cisplatin, or 5-FU, respectively. DOX and cisplatin alone in-
duced apoptosis after 24 to 48 hours, whereas 5-FU did not show
any apoptosis induction alone (see Figure 2). The in vitro apoptosis re-
porter experiments revealed a 54-fold increase of the apoptosis reporter
signals when DOX was added 18 hours before anti-DR5 (DOX→
anti-DR5). Reverse (anti-DR5→DOX) or simultaneous (anti-DR5 +
DOX) application with maximal 33- and 40-fold induction, respec-
tively, showed only additive or slightly synergistic effects compared to
anti-DR5 and DOX monotherapies with 22- and 9-fold induction,
respectively (Figure 5A). Sequential application of cisplatin and anti-
DR5 did not lead to any improved apoptotic effects over simultaneous
dosing, which already led to an impressive synergism with up to 52-fold
induction. Combination of anti-DR5 with 5-FU did not show any
superiority over anti-DR5 monotherapy at all. Comparable results
were obtained when first drug was given 24 hours instead of 18 hours
before second drug. However, shorter (4 hours) or longer (48 and
72 hours) time intervals betweenDOX and anti-DR5 treatment showed
significantly diminished apoptotic effects, indicating an optimized
treatment schedule when DOX is given 18 to 24 hours before anti-
DR5 (Figure 5B).
Guo et al. have shown that the enhanced apoptotic effect of DOX
and TRAIL given sequentially in a glioblastoma xenograft model is
Figure 5. Effects of chemotherapy pretreatment on apoptosis induction and DR5 expression. (A) In vitro bioluminescence apoptosis re-
porter assay to validate apoptosis induction for sequential application of 1 μM DOX, 10 μM cisplatin, or 100 μM 5-FU and 1 μg/ml
anti-DR5 compared to single and simultaneous treatment. In sequential treatments, second drug was added 18 hours after first drug treat-
ment. Bioluminescence signals were normalized to cell viability and expressed in fold induction compared to untreated samples; n = 4;
**P < .01. (B) In vitro bioluminescence apoptosis reporter assay showing apoptosis induction after different time intervals between DOX
and anti-DR5 treatment. Apoptosis reporter activities were measured 6 hours after addition of second-line given anti-DR5. (C) FACS analysis
of anti-DR5–A750 binding to cell surface of D54–caspase-3/7 GloSensor cells after no pretreatment or 18-hour pretreatment with 1 μMDOX,
10 μM cisplatin, or 100 μM 5-FU. (D) FACS analysis of anti-DR5–A750 binding to permeabilized D54–caspase-3/7 GloSensor cells after no
pretreatment or 18-hour pretreatment with 1 μM DOX, 10 μM cisplatin, or 100 μM 5-FU. Cells were permeabilized before anti-DR5–A750
staining to allow intracellular binding of the antibody. (E) Immunofluorescence staining for anti-DR5 binding on the cell surface and in
the cytosol of untreated or DOX-treated D54–caspase-3/7 GloSensor cells. The cells were permeabilized for intracellular binding studies.
In untreated cells, anti-DR5–A750 signals (yellow) were rarely detected on the cell surface (Cholera toxin–A488 staining, green) but fre-
quently detected on intracellular Golgi networks (Golgin-97/Alexa 647 antibody, magenta). In DOX-treated cells, anti-DR5–A750 signals
were intensified on the cell surfaces. Blue, Hoechst cell nucleus staining; arrows, anti-DR5–A750 binding to the cell surface. Original
magnification, ×2500.
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due to an up-regulation of DR5 after DOX treatment [22]. Thus, we
examined by FACS analysis whether pretreatment with DOX,
cisplatin, or 5-FU causes an increased binding of anti-DR5 on the
tumor cell surface. Results of FACS studies revealed that DOX
treatment for 18 hours caused a 2.3-fold higher fluorescence signal
intensity compared to untreated cells. This indicates that DR5 recep-
tors were upregulated on the cell surface (Figure 5C ). Cisplatin and
5-FU treatment led to an only moderate increase in signal intensities
(1.6-fold). Almost identical results were obtained when FACS analy-
sis was performed with A750-labeled mouse anti-human TRAIL R2/
TNFRSF10B antibody (MAB6311; data not shown). In contrast,
when cells were permeabilized before anti-DR5–A750 incubation
to investigate total DR5 protein levels, FACS analysis revealed
almost no differences in signal intensities of untreated cells and cells
pretreated with DOX, cisplatin, or 5-FU (Figure 5D). The almost
unchanged expression levels of total DR5 after treatment were con-
firmed by Western blot analysis (data not shown). This discrepancy
between surface expression and total protein expression of DR5
assumes a quantitative domination of intracellular DR5 protein over
surface-located DR5 receptor, which might explain similar total DR5
protein levels.
To visualize possible differences in intracellular and surface binding
of anti-DR5 in untreated or DOX-treated cells, immunofluorescence
staining and microscopy were performed (Figure 5E ). Zhang et al.
found DR5 receptors located in the trans-golgi network (TGN) of
human melanoma [23]. We have been able to confirm this observation
with the D54–caspase-3/7 GloSensor GBM cells using fluorescence
staining of Golgi networks and co-localization with anti-DR5–A750
signals. Compared to untreated cells, we observed increased binding of
anti-DR5–A750 to the cell surface membrane in the DOX-treated cells.
This indicates that DOX induces translocation of DR5 from cytoplasm
to the tumor cell surface. In concordance with this hypothesis, a shift
of anti-DR5–A750 binding from Golgi structures to cell surface was
detected in permeabilized cells after DOX treatment (Figure 5E).
Expression Profiles after DOX Treatment
To investigate the influence of DOX or anti-DR5 pretreatment in
more detail, the expression profile of 35 apoptosis-related proteins was
examined using the Human Apoptosis Array from R&D Systems
(Figure 6A). The levels of active caspase-3 proteins were concordant
with apoptosis reporter signal intensities for all tested treatments.
Consistent with analysis described above, DOX pretreatment did not
Figure 6. Expression level analysis of apoptosis-related proteins. (A) Human apoptosis array (R&D Systems) showing changes in protein
expression levels of 35 apoptosis-related proteins in duplicates after anti-DR5/DOX treatment. (B) Quantification of protein expression of
13 apoptosis-related proteins of interest. The selected proteins are numbered and their locations on the array are marked in A. Mean pixel
volumes of the duplicates were normalized to reference spots on the array. (C) Western blot analysis for Bid protein expression levels. Bid
antibody detected full-length Bid (upper band, 22 kDa) and truncated Bid (tBid, lower band, 10 kDa). β-Actin served as a loading control.
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lead to an up-regulation of total DR5 protein levels (Figure 6B). High
levels of phosphorylated p53 were seen in DOX-treated cell lysates,
whereas DOX→anti-DR5 and anti-DR5 + DOX treated cells showed
a decrease in antiapoptotic Bad, Bcl-2, XIAP, and survivin but also in
proapoptotic HTRA2/Omi and SMAC/Diablo levels (Figure 6B). The
most obvious difference between DOX→anti-DR5 and anti-DR5 +
DOX in the Apoptosis Array could be found for cytochrome c levels,
where DOX→anti-DR5 led to significant lower cytochrome c levels. In
addition, protein levels of proapoptotic Bid were analyzed by Western
blot analysis. Full-length Bid levels were significantly decreased in
DOX→anti-DR5 and anti-DR5 + DOX treated cells, whereas a trun-
cated, approximately 10 kDa form of Bid was increased (Figure 6C).
Sequential Application of Anti-DR5 and DOX In Vivo
To verify the superiority of sequential DOX→anti-DR5 versus
reverse and simultaneous treatment in vivo, SCID hairless outbred
mice bearing subcutaneous D54–caspase-3/7 GloSensor tumors were
treated with 1 mg/kg anti-DR5–A750 and 10 mg/kg DOX either
simultaneously or sequentially. A time interval of 18 hours, which
was determined in Figure 5B to be the optimal for maximal apop-
tosis induction, was chosen. Apoptosis induction monitored by bio-
luminescence imaging allowed quantifying differences in apoptotic
responses for each application regimen. Fluorescence imaging should
highlight increased anti-DR5–A750 binding to tumor tissues after
DOX pretreatment. When anti-DR5–A750 was given 18 hours after
DOX, an immediate activation of the apoptosis reporter with up to
35-fold induction and significant elevated activities over the study
period of 6 days were observed (Figure 7A). Simultaneous or reverse
application, however, showed only moderate apoptosis induction
(maximal 7- to 12-fold), which was comparable to apoptosis induction
mediated by anti-DR5–A750 monotherapy. The apoptosis reporter
activities of anti-DR5 + DOX and anti-DR5→DOX treated mice
almost returned to control level after 6 days. Induction of apoptosis
by DOX treatment alone was delayed and peaked at day 6 with a
moderate five-fold induction (Figure 7A).
Regarding the different application schedules, fluorescence imaging
using anti-DR5–A750 revealed differences in antibody accumulation
in the tumor region. DOX→anti-DR5–A750 treatment resulted in
significantly enhanced fluorescence signal intensities 6 hours after
anti-DR5 application compared to anti-DR5–A750 + DOX treatment,
suggesting a higher anti-DR5–A750 binding due to increased expres-
sion of DR5 on DOX pretreated tumor cells (Figure 7B). However,
no significant difference becomes detectable at later time points and
in comparison to anti-DR5–A750→ DOX treatment (Figure 7B).
Excluding untreated and anti–DR5-treated mice, no significant dif-
ferences in changes of tumor volume for the different application
schedules were reached (Figure 7C ). This indicates that apoptosis
induction does not immediately translate to tumor volume reduction.
Ex vivo active caspase-3 staining on tumor tissues explanted
24 hours after first drug application confirmed the results of the
in vivo apoptosis imaging. DOX→anti-DR5–A750 treated tumors
revealed strongly enhanced caspase-3 activities, whereas anti-DR5–
A750 + DOX and anti-DR5–A750→DOX treated tumors showed
only moderate increase in caspase-3 activities compared to untreated
controls (Figure 7D, left). Histologic detection of anti-DR5–A750
by fluorescence microscopy also confirmed the in vivo fluorescence
imaging data. Anti-DR5–A750 bound to DOX→anti-DR5–A750
treated tumor cells more efficiently, again indicating an up-regulation
of DR5 (Figure 7D, middle). Interestingly, Ki-67 proliferation staining
revealed no impact on proliferation rate after anti-DR5 monotherapy,
whereas DOX as well as DOX + anti-DR5 and DOX→anti-DR5
treatment inhibit proliferation of GBM tumor cells (Figure 7D, right).
This suggests that, besides DOX-induced up-regulation of DR5, the
proliferation inhibitory effect of DOX might also contribute to the
superiority of DOX before anti-DR5 treatment.
Discussion
Here, we successfully applied the bioluminescence apoptosis reporter
system in a preclinical model of GBM for monitoring pharmaco-
dynamics of anti-DR5 and the enhanced apoptosis induction in a
sequentially given therapy. The apoptosis induction quantified by the
split Luc system correlated with the induction of caspase-3/7 activity
(as shown by ex vivo histologic staining), which activates the Luc light
reaction. The labeling of anti-DR5 with a fluorophore helped to in-
vestigate the mechanism of action of anti-DR5 on the extrinsic apop-
tosis pathway in more detail and allowed to refine the scheduling of
this antibody.
Combined tumor saturation kinetics and pharmacodynamics re-
vealed fast apoptosis induction after anti-DR5 reached the tumor site.
The initial peak of apoptosis reporter signals can be explained by con-
temporaneous apoptosis induction in all tumor cells that are initially
sensitive to anti-DR5 treatment. These cells rapidly abandon protein
synthesis and apoptosis reporter expression, in particular, which leads
to the decline of bioluminescence signals after approximately 16 to
24 hours [24]. Re-application of anti-DR5 reinforced bioluminescence
signal intensities, but less prominent, indicating a smaller group of cells
responding. These observations demonstrate the immediate activation
of the extrinsic apoptosis pathway by anti-DR5 in vivo. Apoptosis
induction by DOX treatment, however, started to occur only after 48
to 72 hours. This time-shifted activation of the two apoptosis pathways
is accounted by the more complex intrinsic activation cascade [2].
Agonistic antibodies to DR5 as well as TRAIL showed promising
antitumor effects in xenograft models [9,25,26] but lack efficacy
in clinics [27–29]. One reason for the lack of efficacy is the de-
velopment of resistance to DR5-dependent monotherapy [26,30].
Therefore, we investigated the potential of sequential application of
anti-DR5 and DOX by apoptosis imaging. The drug partner DOX
was prioritized on the basis of the split Luc assay performed in vitro.
As shown in Figure 2A, DOX induced a concentration- and time-
dependent induction of apoptosis and results depicted in Figure 5 in-
dicate that the apoptosis induction depends on the application schedule
of both drugs. These in vitro observations were confirmed in in vivo
studies. Enhanced apoptosis after sequential application of TRAIL
and DOX has previously been demonstrated in xenograft models of
sarcoma, breast cancer, glioblastoma, myeloma, and prostate cancer
[11,21,22,31,32]. However, these investigations only relied on effi-
cacy or survival studies and ex vivo readouts but not on longitudinal
apoptosis detection.
On the basis of our in vitro and in vivo results, the sequential appli-
cation of DOX→anti-DR5 with a time interval of 18 to 24 hours is
superior to anti-DR5 + DOX and anti-DR5→DOX indicating a syn-
ergistic effect when DNA damages are induced first. As previously
shown, DOX pretreatment can sensitize cells making them more
susceptible for TRAIL-mediated apoptosis [33]. Guo et al. showed that
a possible explanation for the sensitization of GBM cells after DOX
treatment might be the up-regulation of total DR5 and DR5 on the
cell surface [22]. An up-regulation of DR5 is also described after treat-
ments with other chemotherapeutics such as cisplatin, proteasome
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Figure 7. Sequential application of 1 mg/kg anti-DR5–A750 and 10 mg/kg DOX. (A) Time course of mean bioluminescence apoptosis
reporter activities in control mice and mice treated with anti-DR5–A750 + DOX, anti-DR5–A750→DOX, and DOX→anti-DR5–A750. Second
drug was given 18 hours after first drug application. Reporter activities were normalized to tumor volume and expressed in fold induction
to initial time point; n = 5. (B) Time course of mean fluorescence signal intensities showing the accumulation of anti-DR5–A750 in the
tumor site after sequential application of anti-DR5–A750 and DOX. Signals were expressed in percent of mean maximal signal; n = 5.
(C) Changes in tumor volume caused by different sequential application of anti-DR5–A750 and DOX. Mean end point tumor volumes of
each group (5 days after treatment initiation) were calculated and divided by initial mean tumor volumes; n = 5. (D) Representative histo-
logic sections showing active caspase-3 levels, anti-DR5–A750 accumulation, and Ki-67 proliferation status in tumors explanted 24 hours
after first drug application. All fluorescence slides were scanned with the same exposure time (t = 675 ms) to compare images. Original
magnification, ×400.
872 Monitoring Apoptosis in Mice Weber et al. Neoplasia Vol. 15, No. 8, 2013
and histone deacetylase inhibitors, and natural products [34–36].
Figure 5A shows that the combination of cisplatin and anti-DR5
enhances apoptosis induction best when both compounds are given
simultaneously. FACS analyses revealed that cisplatin pretreatment
does not affect DR5 up-regulation on the cell surface in the way
DOX pretreatment does. This might be one reason that the beneficial
effect of cisplatin given before anti-DR5 is not as prominent as after
DOX pretreatment. Therefore, the synergistic effect of combined
cisplatin and anti-DR5 treatment might rely on the manipulation of
different proapoptotic and antiapoptotic components such as Bid
cleavage or down-regulation of antiapoptotic p27 and Bcl-x [36,37].
These manipulations might deploy their proapoptotic effects best when
cisplatin and anti-DR5 are given simultaneously.
Besides an inhibition in tumor cell proliferation caused by DOX
pretreatment, we confirmed DR5 up-regulation and increased anti-
DR5 binding on the cell surface after DOX treatment by FACS
analyses. For the first time, we proved this effect to DOX treatment
in vivo by monitoring anti-DR5–A750 binding to the tumor. Pre-
treatment with DOX led to a higher anti-DR5–A750 accumulation
in the tumor compared to simultaneous application. Guo et al. and
Sheikh et al. could also detect an up-regulation in total DR5 protein
expression for different tumor cell lines [22,38]. In contrast, our
analyses demonstrate that DOX treatment does not modulate total
DR5 protein levels. Bagci-Onder et al. explained such a discrepancy
between cell surface and total DR5 expression with low endogenous
DR5 receptor expression on the cell surface [28]. Because of low DR5
surface expression especially on untreated cells, which we showed by
immunofluorescence microscopy, we suggest that intracellular DR5
proteins predominate DR5 receptors on the cell surface. The cellular
and molecular mechanisms of the translocation process from intra-
cellular DR5 proteins to the cell surface mediated by DOX treatment
need to be further investigated.
Besides DR5 surface up-regulation, further prominent changes in
expression levels of apoptosis-related proteins after DOX treatment
are depicted in Figure 6C . The enhanced apoptotic effect of DOX→
anti-DR5 is presumably mediated by reduced protein levels of the
IAPs survivin and XIAP. These two IAPs seem to be bound and neu-
tralized by SMAC/Diablo and HTRA2/Omi, respectively, which
might explain the low levels of all these four proteins in the apoptosis
array. Besides the IAPs survivin and XIAP, the antiapoptotic mito-
chondrial protein Bcl-2 is also downregulated by DOX→anti-DR5.
The down-regulation of these three antiapoptotic proteins is known
to sensitize tumor cells to enhanced apoptosis through the extrinsic
pathway [39,40]. Interestingly, cytochrome c levels of anti-DR5 +
DOX treated cells are significantly higher than the levels in DOX→
anti–DR5-treated cells. This might be contributed to the exhaustion
of cytochrome c in the cells due to the fast and tremendous apoptosis
induction from 1-fold to 54-fold within 6 hours after time-shifted
anti-DR5 treatment. Chandra et al. have already described decreased
cytochrome c levels in late apoptotic cells [41]. Bad and Bid acting as
proapoptotic proteins appeared to be downregulated by anti-DR5 +
DOX and DOX→anti-DR5 as shown by both the Apoptosis Array
and Western blot, respectively. However, the most potent inducers
of apoptosis are the caspase-cleaved, truncated forms of these proteins,
while full-length protein levels are decreased [42,43]. A truncated,
approximately 10-kDa form of Bid was detected in Western blot
analysis, which was increased in anti-DR5 + DOX and DOX→anti–
DR5-treated cells. The existence of high amounts of truncated Bid
in anti-DR5 + DOX and DOX→anti-DR5 treated cells underlines
that cleavage of Bid is critical and prognostic for enhanced apoptosis
induction through cross-linking of intrinsic and extrinsic apoptosis
pathways [44].
Taken together, the split Luc apoptosis reporter in combination with
fluorescence measurement allowed us to accelerate the optimization of
dosage, application, and combination schedules in a GBM xenograft
model. By monitoring apoptosis in vivo, we demonstrated that the
sequential application of DOX followed by anti-DR5 synergistically
enhances apoptosis that can already be detected 6 hours after anti-
DR5 treatment. We showed that DOX-induced recruitment of DR5
to the cell surface and the proliferation inhibitory effect of DOX result
in a higher susceptibility of D54–caspase-3/7 GloSensor tumor cells
to anti-DR5 treatment and, consequently, to the superiority of the
sequential application of DOX before anti-DR5. The result of our
studies may provide useful information regarding clinical study pro-
tocols and, thus, may support the clinical development of successful
combination therapies with anti-DR5 antibodies.
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